1.	Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Phase: Phase IV Type: Treatment Status: Active Age: 16 to 75 Sponsor: Other Protocol IDs: CGC05MK1002, NCT00188149
2.	Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 15 to 70 Sponsor: Other Protocol IDs: CDR0000531125, EORTC-20051, GELA-H10, IIL-EORTC-20051, EUDRACT-2005-002765-37, EU-20657, NCT00433433
3.	Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 17 and under Sponsor: Other Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
4.	HD18 for Advanced Stages in Hodgkins Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: HD18, NCT00515554
5.	Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-2007-006064-30, 2007-006064-30, CRUK-07/146, NCT00678327
6.	HD17 for Intermediate Stage Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: HD17, NCT01356680
7.	Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 16 to 60 Sponsor: Other Protocol IDs: Casasnovas PHRC N 2010, NCT01358747
8.	Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) Phase: Phase III Type: Diagnostic, Treatment Status: Approved-not yet active Age: 18 to 60 Sponsor: Other Protocol IDs: EORTC-20101-23101, 2011-005473-22, NCT01652261
9.	Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
10.	Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: ISRA2432_CTIL, NCT00392314
11.	Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Phase: Phase II Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: P060239, NCT00503594
12.	Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 30 Sponsor: Other Protocol IDs: CDR0000593560, CRUK-BRD/07/005, EUDRACT-2007-003080-45, EU-20844, BRD/07/005, 18-30, NCT00666484
13.	Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: GITIL - HD0607, NCT00795613
14.	Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 60 Sponsor: NCI, Other Protocol IDs: CDR0000630501, SWOG-S0816, S0816, NCT00822120
15.	Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 00591, Eudract: 2008-007645-31, NCT00989352
16.	Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 to 60 Sponsor: NCI, Other Protocol IDs: CDR0000669076, CALGB-50801, NCT01118026
17.	Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 to 60 Sponsor: NCI, Other Protocol IDs: CDR0000672913, CALGB-50604, NCT01132807
18.	Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0910259M, NCT01124240
19.	Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000702859, ECOG-E2410, E2410, NCT01390584
20.	Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000703682, RTOG-1114, NCT01399372
21.	Prospective Study on HIV-related Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: HIV-HL 2004, NCT01468740
22.	Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: Targeted BEACOPP, NCT01569204
23.	Procarbazine and Lomustine in Recurrent Glioblastoma Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: KNOG-1201, NCT01737346
24.	Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: AMC-068, NCI-2012-01695, U01CA121947, NCT01775475
25.	Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes Phase: No phase specified Type: Diagnostic, Treatment Status: Active Age: 12 to 65 Sponsor: Other Protocol IDs: CIA-HL-1, NCT01304849